|
시장보고서
상품코드
2143344
섬유아세포 성장인자(FGF) 시장 : 제품별, 제품 형태별, 용도별, 최종사용자별, 사용 방법별, 국가별, 지역별 - 세계 산업 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)Fibroblast Growth Factors Market, By Product, By Product Form, By Application, By End User, By Usage, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033 |
||||||
섬유아세포 성장인자(FGF) 시장 규모는 2025년에 3억 1,060만 달러로 평가되며, 2026년부터 2033년까지 CAGR 6.2%로 확대될 것으로 전망됩니다.
섬유아세포 성장인자(FGF)란, 상황에 따라 세포 표면의 티로신 키나아제 수용체를 활성화함으로써 혈관 신생, 상처 치유, 장기 형성 등 수많은 생물학적 역할을 수행하는 분비 단백질군을 말합니다. FGF 분자는 전형적인 구조를 가지고 있으며, 트레포일 모양의 구형 도메인이 분자 자체와 수용체, 그리고 헤파란 황산 보조 인자와의 상호 작용을 담당합니다. 구형 도메인 뒤에 이어지는 이소형 특이적 도메인의 구조에 따라, FGF가 수용체 신호 전달에 미치는 영향과 FGF의 작용 방식(자율신호, 파라크린, 또는 내분비 신호 전달)이 결정됩니다. FGF의 구조 및 번역 후 변형의 가능성 덕분에, 이러한 단백질은 암 조직 내의 세포를 포함하여 거의 모든 세포 유형에 대해 다각적인 효과를 발휘하는 독특한 특성을 가지고 있습니다. 따라서 FGF는 질환(발암 유전자)의 치료, 재생(세포의 증식 및 분화), 그리고 대사 장애의 치료 후보로 자리매김하고 있습니다.
섬유아세포 성장인자 시장 - 시장 역학
시장 수요를 견인하는 재조합 단백질 공학의 발전
재조합 단백질 공학의 발전이 섬유아세포 성장인자 시장을 견인할 것으로 예상됩니다. 섬유아세포 성장인자 생산 분야의 재조합 단백질 공학 발전은 효과적이고 효율적인 섬유아세포 생산 확대에 기여할 것입니다. 이러한 기술은 세포 및 조직의 성장과 그에 따른 치료 및 치유를 촉진할 뿐만 아니라, 연구 개발 및 치료 목적을 위한 섬유아세포 제품의 품질 향상에도 기여합니다. 예를 들어, 2026년 5월에 발표된 '재조합 단백질 의약품 : 2025년판 업데이트' 보고서에 따르면, 합성생물학, 숙주 세포 공학 및 바이오 공정 최적화 분야의 급속한 발전으로 인해 재조합 단백질 치료제 분야에서 진전이 나타나고 있습니다. 초점은 이중특이성항체, 나노바디, 융합 단백질, 자기 조직화 생체 재료로 이동하고 있으며, 또한 2025년까지의 데이터를 바탕으로 한 미국 식품의약국(FDA) 및 유럽의약품청(EMA)의 바이오의약품 누적 및 연간 승인 건수도 기재되어 있습니다. 이러한 진전을 통해 FGF 제품의 품질, 안정성, 유효성 및 치료 용도가 향상될 것으로 기대됩니다.
섬유아세포 성장인자(FGF) 시장 - 시장 세분화 분석:
세계 섬유아세포 성장인자(FGF) 시장은 제품, 제형, 용도, 최종사용자, 사용 방법 및 지역을 기준으로 세분화되어 있습니다.
용도별로는 상처 치유가 중요한 역할을 차지하고 있습니다. 이는 섬유아세포 성장인자(FGF)가 세포 증식, 세포 이동, 관 형성, 혈관 신생 및 조직 재생을 촉진하여 상처의 조기 치유와 피부·조직 복구를 돕기 때문입니다. 2025년 4월, 서모피셔 사이언티픽(Thermo Fisher Scientific)은 이 용도에 특화하여 자사의 FGF-1, FGF-2, FGF-7 및 FGF-10을 기반으로 한 재조합 섬유아세포 성장인자 및 성장호르몬 제품군을 출시했습니다. 이들 성분은 상처 및 조직 치유에 있어 매우 중요한 역할을 한다는 것이 입증되었습니다. FGF-10 재조합 단백질과 관련하여, 서모피셔 사이언티픽(Thermo Fisher Scientific)은 상처 치유, 즉 기본적으로 상처 및 조직 복구에 있어 그 역할에 대해서도 언급하고 있습니다. 이 제품군은 상처 치유 및 조직 복구 연구 응용을 추진하는 데 있어 서모피셔 사이언티픽의 역할을 더욱 공고히 하고 있습니다.
섬유아세포 성장인자 시장 - 지역별 분석
북미는 선진적인 헬스케어 부문, 발달된 생명공학 산업, 그리고 연구 개발에 대한 막대한 투자로 인해 섬유아세포 성장인자 시장에서 두드러진 위치를 차지하고 있습니다. 예를 들어, 2026년 3월 기준 유네스코(UNESCO) 통계연구소에 따르면, 전 세계 연구개발(R&D) 투자는 세계 GDP의 1.71%에서 1.92%로 증가했습니다. 한편, 유럽 및 북미·유럽의 GDP에서 R&D 지출이 차지하는 비율은 2.55%에 달하며, 이는 모든 지역 중 가장 높은 수치입니다. 여전히 73%의 국가들이 GDP의 1% 미만을 연구 개발에 지출하고 있습니다. 연구개발의 중요성과 가치는 더욱 높아지고 있으며, 이는 북미가 FGF의 연구 및 혁신 분야에서 입지를 유지하는 데 한몫하고 있습니다.
인도의 섬유아세포 성장인자 시장 - 국가별 인사이트
인도는 고령 인구가 많은 데다 생활습관병의 증가까지 더해져 이 분야에서 큰 성장 잠재력을 지니고 있습니다. 수요는 상처 관리, 재생 의학 및 종양학 분야의 첨단 치료 기술에 대한 필요성에 의해 주도되고 있습니다. 2025년 1월 기준 NIH Gov의 보고서에 따르면, 인도의 당뇨병 유병률은 도시 지역에서 11%에서 20%, 농촌 지역에서 3%에서 10%에 달합니다. 인도에서는 약 7,700만 명의 성인이 이 질환을 앓고 있습니다. 인도의 사망 원인 중 약 25%는 심장 질환에 기인하며, 18세 이상 인구의 25%가 고혈압을 앓고 있습니다. 인도 인구의 약 5%가 비만이며, 인도 아동 전체의 14.4%가 비만으로 고통받고 있습니다. 또한, 인도 인구의 약 1억 9,730만 명이 정신 질환을 앓고 있습니다. 이러한 국민 건강 동향은 재생의료 및 첨단 상처 치유 치료에 대한 수요를 확실히 높일 것으로 보입니다.
목차
제1장 섬유아세포 성장인자(FGF) 시장 개요
제2장 주요 요약
제3장 섬유아세포 성장인자(FGF) 주요 시장 동향
제4장 섬유아세포 성장인자(FGF) 산업 분석
제5장 섬유아세포 성장인자(FGF) 시장 : 높아지는 지정학적 긴장의 영향
제6장 섬유아세포 성장인자(FGF) 시장 구도
제7장 섬유아세포 성장인자(FGF) 시장 : 제품별
제8장 섬유아세포 성장인자(FGF) 시장 : 제품 형태별
제9장 섬유아세포 성장인자(FGF) 시장 : 용도별
제10장 섬유아세포 성장인자(FGF) 시장 : 최종사용자별
제11장 섬유아세포 성장인자(FGF) 시장 : 사용법별
제12장 섬유아세포 성장인자(FGF) 시장 : 지역별
제13장 주요 벤더 분석 : 섬유아세포 성장인자(FGF) 산업
제14장 AnalystView의 전방위 전망
KSM 26.10.14Fibroblast Growth Factors Market size was valued at US$ 310.6 Million in 2025, expanding at a CAGR of 6.2% from 2026 to 2033.
The Fibroblast Growth Factors (FGFs) refer to the set of secreted proteins which perform a number of biological roles, such as angiogenesis, wound healing and organogenesis, through the activation of cell-surface tyrosine kinase receptors in a manner that is highly context-dependent. The FGF molecules have a typical structure where the trefoil globular domain is responsible for the interaction between the molecule itself and the receptor as well as the heparan sulphate cofactor. The globular domain is followed by the isoform-specific domains whose structure determines the way FGFs affect the receptor signalling and the mode of FGFs' action (autocrine, paracrine or endocrine signalling). The structure of the FGFs as well as the possible post-translational modifications provides these proteins with a unique property to exert a pleiotropic effect on almost all cell types, including those in cancerous tissue. Hence qualifying them as a candidate for treatment of the disease (oncogenes), regeneration (cell proliferation and differentiation) and metabolic disorders.
Fibroblast Growth Factors Market- Market Dynamics
Advancements In Recombinant Protein Engineering To Boost Market Demand
Advancements in recombinant protein engineering are expected to drive the Fibroblast Growth Factors market forward. The development of recombinant protein engineering in the production of fibroblast growth factors will help increase the production of effective and efficient fibroblasts. This type of technology helps to improve the growth of the cells and tissue, as well as their further treatment and healing, and to improve the quality of the fibroblast products for research and therapeutic purposes. For instance, in May 2026, according to the Recombinant Protein Drugs: A 2025 Update report, there has been progress in recombinant protein therapeutics because of the rapid development in synthetic biology, host cell engineering, and bioprocess optimization; the focus has shifted to bispecific antibodies, nanobodies, fusion proteins, and self-assembling biomaterials and also contains cumulative and yearly biologics approvals by both the U.S. FDA and the European Medicines Agency (EMA), which are based on data until 2025. These advancements are expected to enhance FGF product quality, stability, efficacy, and therapeutic applications.
Fibroblast Growth Factors Market- Segmentation Analysis:
The Global Fibroblast Growth Factors Market is segmented on the basis of Product, Product Form, Application, End User, Usage, and Region.
Under application, wound healing plays a key role because fibroblast growth factors (FGFs) support cell proliferation, cell migration, tube formation, angiogenesis, and tissue regeneration that assist in the quicker healing of a wound and repair of skin and tissues. In April 2025, Thermo Fisher Scientific brought out its range of recombinant fibroblast growth factors and growth hormone based on its FGF-1, FGF-2, FGF-7, and FGF-10 specifically for this use, and it has proved to be extremely important for wound and tissue healing. In the case of the FGF-10 recombinant protein, Thermo Fisher Scientific also mentions its role in wound healing, which is basically wound and tissue repair. This portfolio reinforces Thermo Fisher Scientific's role in advancing wound healing and tissue repair research applications.
Fibroblast Growth Factors Market- Geographical Insights
North America holds a notable place in the Fibroblast Growth Factors market due to its advanced healthcare sector, developed biotechnology industry, and substantial spending on research and development. For instance, in March 2026, according to the UNESCO (Org.) Institute for Statistics, the global investment in research and development grew from 1.71% to 1.92% of global GDP, while the R&D expenditure percentage of GDP value in Europe and Northern America & Europe reached 2.55%, which is the highest among all the regions. 73% of countries are still spending less than 1% of their GDP on R&D. The importance and value of R&D have grown further, which helps North America in maintaining its position in FGF research and innovation.
India Fibroblast Growth Factors Market - Country Insights
India offers huge potential for growth in this regard due to its large senior citizen population, along with an increase in lifestyle diseases. The demands are driven by the requirement of advanced treatment techniques to manage wounds, regenerative medicine & oncology. In January 2025, according to the NIH Gov report, the prevalence rate of diabetes cases in the country is between 11% and 20% in urban areas and 3% to 10% in rural areas. Some 77 million adults in India have the disease. Nearly 25% of deaths in India are caused by heart disease, and 25% of people over 18 years old suffer from hypertension. About 5% of the Indian population is obese, while 14.4% of all Indian children suffer from the disease. Around 197.3 million of the Indian population suffers from mental disorders. Such health trends among the population are bound to raise the demand for regenerative and advanced wound healing treatments.
Fibroblast Growth Factors Market- Competitive Landscape:
The Fibroblast Growth Factors market is being affected by several companies that are working towards creating further advancements in the area of protein engineering as well as in other biotechnological efforts. Some of the companies which are working towards making such advancements are Lonza Group, FUJIFILM Wako Pure Chemical, Miltenyi Biotec, Akero Therapeutics, and 89Bio Inc. These companies are trying to make advancements in the area of regenerative medicine, manufacturing methods, and treatment therapies in the areas of oncology, wound healing, and cell therapy. In September 2025, Miltenyi Biotec collaborated with Verismo Therapeutics in order to develop STAR-101 through the supply of clinical-grade lentiviral vectors. These strategic advancements are accelerating innovation and expanding therapeutic applications across the FGF market.
Recent Developments:
In January 2026, FUJIFILM Wako Pure Chemical initiated the manufacture of its GMP CHIR99021 GSK-3B inhibitor on a commercial scale for use in cell culture processes, adding to its range of reagents that facilitate the research and production of cell therapies.
In September 2025, 89bio signed a merger agreement for acquisition by Roche, integrating Roche's development, manufacturing, and marketing capabilities with 89bio's pegozafermin, an FGF21 analogue under development for MASH.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FIBROBLAST GROWTH FACTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Thermo Fisher Scientific
- R&D Systems (Bio-Techne)
- Merck KGaA (Sigma-Aldrich)
- Abcam
- Cell Signaling End User
- GenScript Biotech
- Lonza Group
- Miltenyi Biotec
- FUJIFILM Wako Pure Chemical
- MedChemExpress
- Proteintech Group
- Elabscience Biotech
- ACROBiosystems
- STEMCELL Technologies
- Sino Biological
- Creative BioMart
- BioLegend
- Others
GLOBAL FIBROBLAST GR MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- FGF21
- FGF7
- FGF23
- FGF1
- FGF10
- FGF2
- FGF19
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY PRODUCT FORM- MARKET ANALYSIS, 2020 - 2033
- Finished Formulations
- Research Grade
- Kits & Diagnostic Reagents
- GMP Grade
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033
- Cell Therapy
- Dermatology
- Oncology
- Cardiovascular Disease & Diabetes
- Wound Healing
- Hematology
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Contract Research & Manufacturing Organizations
- Pharmaceutical & Biotechnology Companies
- Research Centers & Academic Institutes
- Others
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY USAGE- MARKET ANALYSIS, 2020 - 2033
- Topical FGFs
- Clinical-Stage Use
- Implant/Scaffold-Integrated FGFs
- In-Vivo Preclinical Use
- Injectable FGFs
- In-Vitro Use
GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Table of Contents
1. Fibroblast Growth Factors Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Fibroblast Growth Factors Market Snippet by Product
- 2.1.2. Fibroblast Growth Factors Market Snippet by Product Form
- 2.1.3. Fibroblast Growth Factors Market Snippet by Application
- 2.1.4. Fibroblast Growth Factors Market Snippet by End User
- 2.1.5. Fibroblast Growth Factors Market Snippet by Usage
- 2.1.6. Fibroblast Growth Factors Market Snippet by Country
- 2.1.7. Fibroblast Growth Factors Market Snippet by Region
- 2.2. Competitive Insights
3. Fibroblast Growth Factors Key Market Trends
- 3.1. Fibroblast Growth Factors Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Fibroblast Growth Factors Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Fibroblast Growth Factors Market Opportunities
- 3.4. Fibroblast Growth Factors Market Future Trends
4. Fibroblast Growth Factors Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Fibroblast Growth Factors Market : Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Fibroblast Growth Factors Market Landscape
- 6.1. Fibroblast Growth Factors Market Share Analysis, 2025
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Fibroblast Growth Factors Market - By Product
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
- 7.1.2. FGF21
- 7.1.3. FGF7
- 7.1.4. FGF23
- 7.1.5. FGF1
- 7.1.6. FGF10
- 7.1.7. FGF2
- 7.1.8. FGF19
- 7.1.9. Others
8. Fibroblast Growth Factors Market - By Product Form
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Product Form, 2025 & 2033 (%)
- 8.1.2. Finished Formulations
- 8.1.3. Research Grade
- 8.1.4. Kits & Diagnostic Reagents
- 8.1.5. GMP Grade
9. Fibroblast Growth Factors Market - By Application
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
- 9.1.2. Cell Therapy
- 9.1.3. Dermatology
- 9.1.4. Oncology
- 9.1.5. Cardiovascular Disease & Diabetes
- 9.1.6. Wound Healing
- 9.1.7. Hematology
- 9.1.8. Others
10. Fibroblast Growth Factors Market - By End User
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
- 10.1.2. Contract Research & Manufacturing Organizations
- 10.1.3. Pharmaceutical & Biotechnology Companies
- 10.1.4. Research Centers & Academic Institutes
- 10.1.5. Others
11. Fibroblast Growth Factors Market - By Usage
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By Usage, 2025 & 2033 (%)
- 11.1.2. Topical FGFs
- 11.1.3. Clinical-Stage Use
- 11.1.4. Implant/Scaffold-Integrated FGFs
- 11.1.5. In-Vivo Preclinical Use
- 11.1.6. Injectable FGFs
- 11.1.7. In-Vitro Use
12. Fibroblast Growth Factors Market - By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Fibroblast Growth Factors Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
- 12.2.9. U.S.
- 12.2.10. Canada
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Fibroblast Growth Factors Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
- 12.3.9. Germany
- 12.3.10. UK
- 12.3.11. France
- 12.3.12. Italy
- 12.3.13. Spain
- 12.3.14. The Netherlands
- 12.3.15. Sweden
- 12.3.16. Russia
- 12.3.17. Poland
- 12.3.18. Denmark
- 12.3.19. Rest of Europe
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Fibroblast Growth Factors Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
- 12.4.9. China
- 12.4.10. India
- 12.4.11. Japan
- 12.4.12. South Korea
- 12.4.13. Australia
- 12.4.14. Indonesia
- 12.4.15. Thailand
- 12.4.16. Philippines
- 12.4.17. Taiwan
- 12.4.18. Vietnam
- 12.4.19. Rest of APAC
- 12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Fibroblast Growth Factors Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
- 12.5.9. Brazil
- 12.5.10. Mexico
- 12.5.11. Argentina
- 12.5.12. Colombia
- 12.5.13. Rest of LATAM
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Fibroblast Growth Factors Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.10. UAE
- 12.6.11. Israel
- 12.6.12. Turkey
- 12.6.13. Algeria
- 12.6.14. Egypt
- 12.6.15. Iran
- 12.6.16. Qatar
- 12.6.17. Rest of MEA
13. Key Vendor Analysis- Fibroblast Growth Factors Industry
- 13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. Thermo Fisher Scientific
- 13.2.2. R&D Systems (Bio-Techne)
- 13.2.3. Merck KGaA (Sigma-Aldrich)
- 13.2.4. Abcam
- 13.2.5. Cell Signaling End User
- 13.2.6. GenScript Biotech
- 13.2.7. Lonza Group
- 13.2.8. Miltenyi Biotec
- 13.2.9. FUJIFILM Wako Pure Chemical
- 13.2.10. MedChemExpress
- 13.2.11. Proteintech Group
- 13.2.12. Elabscience Biotech
- 13.2.13. ACROBiosystems
- 13.2.14. STEMCELL Technologies
- 13.2.15. Sino Biological
- 13.2.16. Creative BioMart
- 13.2.17. BioLegend
- 13.2.18. Others
14. 360 Degree AnalystView
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
